Notably, ER+, as well as ER+R BC cells exhibited a significant reduction of cell viability after treatment with dinaciclib, whose efficacy was further increased by silencing of SAM68 (Fig. 5A and Supplementary Fig. S5B, C). Here, KHDRBS1 is linked to breast cancer.